GENEDX HOLDINGS CORP.

NASDAQ: WGS (GeneDx Holdings Corp.)

最近更新时间: 4天之前, 7:22PM

166.95

1.34 (0.81%)

前收盘价格 165.61
收盘价格 165.21
成交量 158,702
平均成交量 (3个月) 529,790
市值 4,825,620,992
市盈率 (P/E TTM) 1,391.25
预期市盈率 (P/E Forward) 238.10
价格/销量 (P/S) 11.36
股市价格/股市净资产 (P/B) 15.95
52周波幅
55.17 (-66%) — 170.75 (2%)
利润日期 28 Oct 2025
营业毛利率 -11.69%
营业利益率 (TTM) -5.22%
稀释每股收益 (EPS TTM) -1.39
季度收入增长率 (YOY) 39.60%
总债务/股东权益 (D/E MRQ) 44.61%
流动比率 (MRQ) 3.25
营业现金流 (OCF TTM) -1.90 M
杠杆自由现金流 (LFCF TTM) 17.79 M
资产报酬率 (ROA TTM) -1.84%
股东权益报酬率 (ROE TTM) -16.61%

市场趋势

短期 中期
行业 Health Information Services (US) 混合的 混合的
Health Information Services (全球的) 混合的 混合的
股票 GeneDx Holdings Corp. 看涨 看涨

AIStockmoo 评分

-0.5
分析师共识 -1.5
内部交易活动 NA
价格波动 -5.0
技术平均移动指标 2.5
技术振荡指标 2.0
平均 -0.50

相关股票

股票 市值 DY P/E(TTM) P/B
WGS 5 B - 1,391.25 15.95
HQY 9 B - 60.54 4.21
WAY 7 B - 54.32 2.20
BTSG 7 B - 65.85 3.59
RCM 6 B - - 2.14
PRVA 3 B - 165.21 4.23

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.

部门 Healthcare
行业 Health Information Services
投资方式 Small Growth
内部持股比例 12.56%
机构持股比例 102.71%

所有权

姓名 日期 持有股份
Corvex Management Lp 30 Sep 2025 3,058,629
Oracle Investment Management Inc 30 Sep 2025 889,954
Summit Partners Public Asset Management, Llc 30 Sep 2025 823,567
52周波幅
55.17 (-66%) — 170.75 (2%)
目标价格波幅
140.00 (-16%) — 170.00 (1%)
170.00 (Guggenheim, 1.83%) 购买
160.00 (-4.16%)
140.00 (Wells Fargo, -16.14%) 保留
140.00 (Piper Sandler, -16.14%) 购买
平均值 155.00 (-7.16%)
总计 4 购买, 1 保留
平均价格@调整类型 132.13
公司 日期 目标价格 调整类型 价格@调整类型
Wells Fargo 04 Nov 2025 140.00 (-16.14%) 保留 139.49
BTIG 29 Oct 2025 165.00 (-1.17%) 购买 131.76
22 Oct 2025 140.00 (-16.14%) 购买 121.01
Canaccord Genuity 29 Oct 2025 160.00 (-4.16%) 购买 131.76
20 Oct 2025 155.00 (-7.16%) 购买 127.03
Guggenheim 29 Oct 2025 170.00 (1.83%) 购买 131.76
Piper Sandler 11 Sep 2025 140.00 (-16.14%) 购买 125.89

该时间范围内无数据。

日期 类型 细节
06 Nov 2025 公告 GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting
04 Nov 2025 公告 GeneDx to Participate in Upcoming Investor Conferences
28 Oct 2025 公告 GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
27 Oct 2025 公告 GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims
22 Oct 2025 公告 GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
20 Oct 2025 公告 GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing
15 Oct 2025 公告 Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
14 Oct 2025 公告 GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer
13 Oct 2025 公告 GeneDx to Partner with Florida’s Sunshine Genetics Network, Launching Nation’s First State-Backed Genomic Newborn Screening Program
09 Oct 2025 公告 GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program
08 Oct 2025 公告 GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
07 Oct 2025 公告 GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025
01 Oct 2025 公告 GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award
30 Sep 2025 公告 GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth
25 Sep 2025 公告 GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference
18 Sep 2025 公告 GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票